172 related articles for article (PubMed ID: 38192537)
1. Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers.
Myojin Y; McCallen JD; Ma C; Bauer KC; Ruf B; Benmebarek MR; Green BL; Wabitsch S; McVey JC; Fu C; Xie C; Greten TF
JHEP Rep; 2024 Jan; 6(1):100959. PubMed ID: 38192537
[TBL] [Abstract][Full Text] [Related]
2. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
3. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X
J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
[TBL] [Abstract][Full Text] [Related]
5. Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma.
Allard B; Jacoberger-Foissac C; Cousineau I; Bareche Y; Buisseret L; Chrobak P; Allard D; Pommey S; Ah-Pine F; Duquenne S; Picard F; Stagg J
Cell Rep Med; 2023 Sep; 4(9):101188. PubMed ID: 37729873
[TBL] [Abstract][Full Text] [Related]
6. Small molecule AZD4635 inhibitor of A
Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
[TBL] [Abstract][Full Text] [Related]
7. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
8. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
9. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
10. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
Lu JC; Zhang PF; Huang XY; Guo XJ; Gao C; Zeng HY; Zheng YM; Wang SW; Cai JB; Sun QM; Shi YH; Zhou J; Ke AW; Shi GM; Fan J
J Hematol Oncol; 2021 Nov; 14(1):200. PubMed ID: 34838121
[TBL] [Abstract][Full Text] [Related]
11. Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.
Sun C; Wang B; Hao S
Front Immunol; 2022; 13():837230. PubMed ID: 35386701
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
13. A2A adenosine receptor protects tumors from antitumor T cells.
Ohta A; Gorelik E; Prasad SJ; Ronchese F; Lukashev D; Wong MK; Huang X; Caldwell S; Liu K; Smith P; Chen JF; Jackson EK; Apasov S; Abrams S; Sitkovsky M
Proc Natl Acad Sci U S A; 2006 Aug; 103(35):13132-7. PubMed ID: 16916931
[TBL] [Abstract][Full Text] [Related]
14. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
Steingold JM; Hatfield SM
Front Immunol; 2020; 11():570041. PubMed ID: 33117358
[TBL] [Abstract][Full Text] [Related]
15. Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.
Ou DL; Lin YY; Hsu CL; Lin YY; Chen CW; Yu JS; Miaw SC; Hsu PN; Cheng AL; Hsu C
Liver Cancer; 2019 May; 8(3):155-171. PubMed ID: 31192153
[TBL] [Abstract][Full Text] [Related]
16. Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody.
Tej GNVC; Neogi K; Nayak PK
Int Immunopharmacol; 2019 Dec; 77():106002. PubMed ID: 31711939
[TBL] [Abstract][Full Text] [Related]
17. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.
Willingham SB; Ho PY; Hotson A; Hill C; Piccione EC; Hsieh J; Liu L; Buggy JJ; McCaffery I; Miller RA
Cancer Immunol Res; 2018 Oct; 6(10):1136-1149. PubMed ID: 30131376
[TBL] [Abstract][Full Text] [Related]
18. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice.
Armstrong JM; Chen JF; Schwarzschild MA; Apasov S; Smith PT; Caldwell C; Chen P; Figler H; Sullivan G; Fink S; Linden J; Sitkovsky M
Biochem J; 2001 Feb; 354(Pt 1):123-30. PubMed ID: 11171087
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Combination Strategies for the A
Voronova V; Peskov K; Kosinsky Y; Helmlinger G; Chu L; Borodovsky A; Woessner R; Sachsenmeier K; Shao W; Kumar R; Pouliot G; Merchant M; Kimko H; Mugundu G
Front Immunol; 2021; 12():617316. PubMed ID: 33737925
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
Giuffrida L; Sek K; Henderson MA; Lai J; Chen AXY; Meyran D; Todd KL; Petley EV; Mardiana S; Mølck C; Stewart GD; Solomon BJ; Parish IA; Neeson PJ; Harrison SJ; Kats LM; House IG; Darcy PK; Beavis PA
Nat Commun; 2021 May; 12(1):3236. PubMed ID: 34050151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
